Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

Weisel, Katja; Spencer, Andrew; Lentzsch, Suzanne; Avet-Loiseau, Herve; Mark, Tomer; Spicka, Ivan; Masszi, Tamas; Lauri, Birgitta; Levin, Mark-David; Bosi, Alberto; Hungria, Vania; Cavo, Michele; Lee, Je-Jung; Nooka, Ajay; Quach, Hang; Munder, Markus; Lee, Cindy; Barreto, Wolney; Corradini, Paolo; Min, Chang-Ki; Chanan-Khan, Asher; Horvath, Noemi; Capra, Marcelo; BEKSAÇ, MERAL; Ovilla, Roberto; Jo, Jae-Cheol; Shin, Ho-Jin; Sonneveld, Pieter; Casneuf, Tineke; DeAngelis, Nikki; Amin, Himal; Ukropec, Jon; Kobos, Rachel; Mateos, Maria-Victoria

doi:10.1186/s13045-020-00948-5

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

Copy For Citation

Weisel K., Spencer A., Lentzsch S., Avet-Loiseau H., Mark T. M., Spicka I., ...More

JOURNAL OF HEMATOLOGY & ONCOLOGY, vol.13, no.1, 2020 (SCI-Expanded)

Publication Type: Article / Article
Volume: 13 Issue: 1
Publication Date: 2020
Doi Number: 10.1186/s13045-020-00948-5
Journal Name: JOURNAL OF HEMATOLOGY & ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE, Directory of Open Access Journals
Keywords: Clinical trials, Multiple myeloma, Myeloma therapy, INTERGROUPE FRANCOPHONE, ANTIBODY DARATUMUMAB, SURVIVAL, ABNORMALITIES, CONSENSUS
Ankara University Affiliated: Yes

Abstract

Background: Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM).